Reuters logo
BRIEF-Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017
September 11, 2017 / 8:06 AM / 9 days ago

BRIEF-Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

Sept 11 (Reuters) - Curis Inc

* Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

* Presented preliminary data from initial 34 patients with cancer treated in dose escalation stage of phase 1 trial of CA-170 conducted in US, South Korea, Spain

* Aurigene Discovery Technologies Limited announced plans to initiate a phase 2 trial of CA-170 to be conducted at sites in India Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below